Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keytruda Is King, But Merck Faces Questions About Business Development

Executive Summary

Keytruda continues to break records on the strength of its efficacy in lung cancer, and shows no signs of slowing down. But analysts were intrigued by repeated mentions of business development during Merck’s third quarter earnings call.

Advertisement

Related Content

Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate
Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead
Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory
Key Cancer Data To Be Unveiled At ESMO In Munich
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences
First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Zoetis raises $2.2bn in IPO but other pharma majors to retain animal health

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124062

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel